Search CTL/CD8+ T-Cell Epitope Database

Found 13 matching records:

Displaying record number 58542

Download this epitope record as JSON.

HXB2 Location	gp160(787-795) gp41(276-284) DNA(8583..8609)	gp160 Epitope Map
Author Location	gp41
Epitope	`RRGWEVLKY`	Epitope Alignment
Epitope Name	A1-RY9
Subtype	B
Species (MHC/HLA)	human(A*01)
Immunogen	HIV-1 infection
Country	United States
Experimental methods
Keywords	review, rate of progression, acute/early infection

Notes

Acute infection with HIV-1 is accompanied by high viral load (VL) and loss of CD4 helper T cells. Early inhibition of VL by CTL results in a 'set point' that is correlated with disease progression. The early CTL response during acute infection if successful is to a known immunodominant epitope. Following, chronic infection sets in with a greater breadth and magnitude of CTL response, but no change in VL or HIV-1 replication. Immunodominant epitopes from several studies that help set a lower VL during acute phase are listed in this review.
RRGWEVLKY, A1-RY9, when restricted by HLA-A*01 is recognized by 17% acutely-infected and 14% chronically-infected North American subjects expressing the same HLA allele. HLA-A*01 is present at a frequency of 28.7% in North American white populations.

References

Streeck2010 Hendrik Streeck and Douglas F. Nixon. T Cell Immunity in Acute HIV-1 Infection. J. Infect. Dis., 202(Suppl 2):S302-8, 15 Oct 2010. PubMed ID: 20846037. Show all entries for this paper.

Displaying record number 59308

Download this epitope record as JSON.

HXB2 Location	gp160(787-795) gp41(276-284) DNA(8583..8609)	gp160 Epitope Map
Author Location	gp41
Epitope	`RRGWEVLKY`	Epitope Alignment
Epitope Name	RY9
Species (MHC/HLA)	human(A*01)
Immunogen	HIV-1 infection
Experimental methods	CD8 T-cell Elispot - IFNγ
Keywords	rate of progression

Notes

620 patients in early/acute stages of infection were screened for Elispot responses to optimally defined epitopes to find associations between specific CTL responses and long-term control of HIV-1. Seven epitope-specific responses were associated with delayed initiation of ART, and 12 were associated with a more rapid initiation of therapy. While initial viremia, HLA Class I genotype and viral set points were associated, breadth and magnitude of response did not influence early viral set point. A broader CTL response to Gag, however, associates with slower disease progression.
Initial specificity of CTL response rather than restricting HLA-I molecule contributes to disease control.
The HLA-A*01-restricted epitope RRGWEVLKY was associated with accelerated initiation of ART.

References

Streeck2014 Hendrik Streeck, Richard Lu, Noor Beckwith, Mark Milazzo, Michelle Liu, Jean-Pierre Routy, Susan Little, Heiko Jessen, Anthony D. Kelleher, Frederick Hecht, Rafick-Pierre Sekaly, Galit Alter, David Heckerman, Mary Carrington, Eric S. Rosenberg, and Marcus Altfeld. Emergence of Individual HIV-Specific CD8 T Cell Responses during Primary HIV-1 Infection Can Determine Long-Term Disease Outcome. J. Virol., 88(21):12793-12801, Nov 2014. PubMed ID: 25165102. Show all entries for this paper.

Displaying record number 52521

Download this epitope record as JSON.

HXB2 Location	gp160(787-795) gp41(276-284) DNA(8583..8609)	gp160 Epitope Map
Author Location	gp160(787-795)
Epitope	`RRGWEVLKY`	Epitope Alignment
Species (MHC/HLA)	human(A*01:01)
Immunogen	HIV-1 infection
Experimental methods
Keywords	optimal epitope, A-list

References

Llano2019 Anuska Llano, Samandhy Cedeño, Sandra Silva Arrieta, and Christian Brander. The 2019 Optimal HIV CTL Epitopes Update: Growing Diversity in Epitope Length and HLA restriction. 2019. Show all entries for this paper.

Displaying record number 57090

Download this epitope record as JSON.

HXB2 Location	gp160(787-795) gp41(276-284) DNA(8583..8609)	gp160 Epitope Map
Author Location	gp41(276-284 DU422)
Epitope	`RRGWEVLKY`	Epitope Alignment
Subtype	B
Species (MHC/HLA)	human(A*01:01)
Immunogen	in vitro stimulation or selection
Experimental methods	CD8 T-cell Elispot - IFNγ, Chromium-release assay, Tetramer binding
Keywords	dendritic cells

Notes

Three types of myeloid dendritic cells - monocytic dendritic cells, Langerhans cells, and interstitial dermal-intestinal dendritic cells - were shown to be able to prime CD8+ T-cell responses to HIV-1. Primed monocytic dendritic cells from 2 uninfected adult donors had broad primary T-cell reactivity, reacting with 15mers containing 42 known epitopes in Gag, Env, and Nef.
One of the reactive 15mers contained optimal epitope RRGWEVLKY, which was restricted by HLA A*0101.

References

Colleton2009 Bonnie A. Colleton, Xiao-Li Huang, Nada M. Melhem, Zheng Fan, Luann Borowski, Giovanna Rappocciolo, and Charles R. Rinaldo. Primary Human Immunodeficiency Virus Type 1-Specific CD8+ T-Cell Responses Induced by Myeloid Dendritic Cells. J. Virol., 83(12):6288-6299, Jun 2009. PubMed ID: 19357176. Show all entries for this paper.

Displaying record number 61000

Download this epitope record as JSON.

HXB2 Location	gp160(787-795) gp41(276-284) DNA(8583..8609)	gp160 Epitope Map
Author Location	gp160(787-795)
Epitope	`RRGWEVLKY`	Epitope Alignment
Subtype	B
Species (MHC/HLA)	human(A*01:01)
Immunogen	HIV-1 infection
Patient MHC/HLA	71101: A01:01, A03:01, B08:01, B35:03, C04:01, C07:01
Country	United States
Experimental methods	CD8 T-cell Elispot - IFNγ
Keywords	acute/early infection

Notes

The extent to which set-point viremia is affected by early HIV-infection T cell responses to either conserved or variable epitopes was studied. 23 ART-naive subjects were characterized for CTL responses for 6 months, postinfection. While most CTL responses (73/123) were targeted against variable HIV-1 epitopes, recognition of conserved epitopes (16/123) was associated with lower set point viremia. This was independent of HLA type and also functional avidity of the CTL response. Most of the conserved responses were targeted to Gag and Pol epitopes.
RRGWEVLKY, restricted by A*0101, was recognized by 1 patient with the restricting allele.

References

Kunwar2013 Pratima Kunwar, Natalie Hawkins, Warren L. Dinges, Yi Liu, Erin E. Gabriel, David A. Swan, Claire E. Stevens, Janine Maenza, Ann C. Collier, James I. Mullins, Tomer Hertz, Xuesong Yu, and Helen Horton. Superior Control of HIV-1 Replication by CD8+ T Cells Targeting Conserved Epitopes: Implications for HIV Vaccine Design. PLoS One, 8(5):e64405, 2013. PubMed ID: 23741326. Show all entries for this paper.

Displaying record number 56460

Download this epitope record as JSON.

HXB2 Location	gp160(787-795) gp41(276-284) DNA(8583..8609)	gp160 Epitope Map
Author Location	gp41
Epitope	`RRGWEVLKY`	Epitope Alignment
Epitope Name	RY9(gp41)
Subtype	B
Species (MHC/HLA)	human(A1)
Immunogen	HIV-1 infection
Country	China
Experimental methods	CD8 T-cell Elispot - IFNγ
Keywords	non-susceptible form, chronic infection

Notes

49 ART-naive chronically HIV-1 infected Chinese subjects' CTLs were tested with 413 OLPs in IFN-γ assays, determining optimal epitopes specific for Chinese Clade B HIV-1 sequences.
An inverse correlation was found between CTL response and viral load.
Targeted peptides have lower entropy than peptides that are not CTL targeted. This correlation is independent of HLA-restriction.
The tested peptide sequence, LLGRRGWEaLKYLWNLL, contains a variant, RRGWEaLKY that differs by 1 substitution from the previously described HLA-A1 optimal epitope RRGWEVLKY. None of the 4 HLA-A1 carriers responded to the variant RRGWEaLKY.

References

Zhai2008 Song Zhai, Yan Zhuang, Yang Song, Shu Li, Dedong Huang, Wenzhen Kang, Xinhong Li, Qi Liao, Yanhou Liu, Zhongfang Zhao, Yichen Lu, and Yongtao Sun. HIV-1-Specific Cytotoxic T Lymphocyte (CTL) Responses Against Immunodominant Optimal Epitopes Slow the Progression of AIDS in China. Curr. HIV Res., 6(4):335-350, Jun 2008. PubMed ID: 18691032. Show all entries for this paper.

Displaying record number 57928

Download this epitope record as JSON.

HXB2 Location	gp160(787-795) gp41(276-284) DNA(8583..8609)	gp160 Epitope Map
Author Location	Env(787-795)
Epitope	`RRGWEVLKY`	Epitope Alignment
		Show epitope variants
Subtype	B
Species (MHC/HLA)	human(A1)
Immunogen	HIV-1 infection
Patient MHC/HLA	A01:01, A03:01, B08:01, B35:03, C04:01, C07:01
Country	United States
Experimental methods	CD8 T-cell Elispot - IFNγ
Keywords	acute/early infection

Notes

The study tracked changes in amino acid residues across the whole genome over time during the first year of infection in 11 individuals representing 4 donor-recipient pairs and 3 independent seroconverters. 9 of the 11 individuals were enrolled during acute infection. In most cases, a single founder virus underwent selection, primarily in env and nef. Mutations were detected in the first week, and became consensus as early as 21 days post-onset of symptoms. Putative escape mutations were often rapidly replaced with mutually-exclusive mutations nearby. Escape mutations were more frequent than reversions.
Previously-documented A1-restricted epitope RRGWEVLKY was recognized by EliSpot assay in 1 HIV-positive A*0101-positive patient. The patient was negative at day 7, and positive by day 127 post-seroconversion.

References

Herbeck2011 Joshua T. Herbeck, Morgane Rolland, Yi Liu, Sherry McLaughlin, John McNevin, Hong Zhao, Kim Wong, Julia N. Stoddard, Dana Raugi, Stephanie Sorensen, Indira Genowati, Brian Birditt, Angela McKay, Kurt Diem, Brandon S. Maust, Wenjie Deng, Ann C. Collier, Joanne D. Stekler, M. Juliana McElrath, and James I. Mullins. Demographic Processes Affect HIV-1 Evolution in Primary Infection before the Onset of Selective Processes. J. Virol., 85(15):7523-7534, Aug 2011. PubMed ID: 21593162. Show all entries for this paper.

Displaying record number 54219

Download this epitope record as JSON.

HXB2 Location	gp160(787-795) gp41(276-284) DNA(8583..8609)	gp160 Epitope Map
Author Location	gp41
Epitope	`RRGWEVLKY`	Epitope Alignment
Epitope Name	A1-RY9(gp41)
Species (MHC/HLA)	human(A1)
Immunogen	HIV-1 infection
Experimental methods	CD8 T-cell Elispot - IFNγ
Keywords	rate of progression, immunodominance, early-expressed proteins

Notes

Immunodominant HIV epitopes in early, primary infection of CTLs were identified and the relative contributions of immune responses restricted to individual HLA class I molecules were studied.
This epitope-HLA combination was recognized. The most frequently recognized epitopes also elicited the greatest CTL response.
HIV-1 Epitope sequence variability was not correlated with immunodominant versus immune sub-dominant responses.
HLA-B*57 and HLA-B*27 restricted responses were the strongest in these early and acute infections - due to dominant responses to a single epitope in each case (TW10 for B*57 and KK10 for B*27).
In the presence of HLA-B*57 and HLA-B*27 restricted responses, the relative contributions of other restricting HLA dropped greatly.

References

Altfeld2006 Marcus Altfeld, Elizabeth T. Kalife, Ying Qi, Hendrik Streeck, Mathias Lichterfeld, Mary N. Johnston, Nicole Burgett, Martha E. Swartz, Amy Yang, Galit Alter, Xu G. Yu, Angela Meier, Juergen K. Rockstroh, Todd M. Allen, Heiko Jessen, Eric S. Rosenberg, Mary Carrington, and Bruce D. Walker. HLA Alleles Associated with Delayed Progression to AIDS Contribute Strongly to the Initial CD8+ T Cell Response against HIV-1. PLoS Med., 3(10):e403, Oct 2006. PubMed ID: 17076553. Show all entries for this paper.

Displaying record number 52637

Download this epitope record as JSON.

HXB2 Location	gp160(787-795) gp41(276-284) DNA(8583..8609)	gp160 Epitope Map
Author Location	gp41(787-795)
Epitope	`RRGWEVLKY`	Epitope Alignment
Species (MHC/HLA)	human(A1)
Immunogen	HIV-1 infection
Patient MHC/HLA	A1, A1, B14, B8, Cw7, Cw8
Experimental methods	CD8 T-cell Elispot - IFNγ
Keywords	binding affinity, acute/early infection, early-expressed proteins

Notes

CTL epitope responses were mapped in 21 men within 15-92 days post-HIV-1 infection. Subjects initially showed a narrow immune response with a mean of 2.3 epitopes recognized per patient. The immune response broadened later in infection. No correlation between the plasma viral load and the number of recognized epitopes or the frequency of IFNγ-secreting cells was observed, and there was no correlation between the functional avidity of a response and the abundance of IFNγ-secreting cells that recognized the epitope. The first epitopes to be recognized tended not to be the most avid, and earliest responses tended to be directed against Nef, Tat, Vpr, and Env.
All HIV-1 proteins except Vpu were recognized, and responses to a total of 41 optimal epitopes were characterized; 24 had been identified previously. 48% of the total T-cell responses were directed against Nef and 43% were directed against Gag.
More common HLA alleles were less frequently used in primary infection than less common alleles, for example A3, B35, B57, and B62 were more frequently recognized than A1, A2, A30, and A44.

References

Cao2003 Jianhong Cao, John McNevin, Sarah Holte, Lisa Fink, Lawrence Corey, and M. Juliana McElrath. Comprehensive Analysis of Human Immunodeficiency Virus Type 1 (HIV-1)-Specific Gamma Interferon-Secreting CD8+ T Cells in Primary HIV-1 Infection. J. Virol., 77(12):6867-6878, Jun 2003. PubMed ID: 12768006. Show all entries for this paper.

Displaying record number 60203

Download this epitope record as JSON.

HXB2 Location	gp160(787-795) gp41(276-284) DNA(8583..8609)	gp160 Epitope Map
Author Location	Env(787-795)
Epitope	`RRGWEVLKY`	Epitope Alignment
Epitope Name	RY9
Species (MHC/HLA)	human(B*57)
Immunogen	HIV-1 infection
Experimental methods	CD8 T-cell Elispot - IFNγ, Flow cytometric T-cell cytokine assay
Keywords	rate of progression, optimal epitope, chronic infection

Notes

Correlation between HLA class I and spontaneous control of HIV-1 was significant for 7-8 epitopes when 341 chronic, HIV-infected subjects, divided into controllers and non-controllers, were tested for EliSpot responses to 257 optimally defined epitopes. 21 epitopes were associated with viral progression. Protective epitopes tend to cluster in regions of critical stability for the protein, therefore constraining escape.
RRGWEVLKY had a significantly positive association with HLA B*57; it was recognized by 6/87 B*57-positive subjects and 3/191 B*57-negative subjects.

References

Pereyra2014 Florencia Pereyra, David Heckerman, Jonathan M. Carlson, Carl Kadie, Damien Z. Soghoian, Daniel Karel, Ariel Goldenthal, Oliver B. Davis, Charles E. DeZiel, Tienho Lin, Jian Peng, Alicja Piechocka, Mary Carrington, and Bruce D. Walker. HIV Control Is Mediated in Part by CD8+ T-Cell Targeting of Specific Epitopes. J. Virol., 88(22):12937-12948, Nov 2014. PubMed ID: 25165115. Show all entries for this paper.

Displaying record number 60201

Download this epitope record as JSON.

HXB2 Location	gp160(787-795) gp41(276-284) DNA(8583..8609)	gp160 Epitope Map
Author Location	Env(787-795)
Epitope	`RRGWEVLKY`	Epitope Alignment
Epitope Name	RY9
Species (MHC/HLA)	human(C*02)
Immunogen	HIV-1 infection
Experimental methods	CD8 T-cell Elispot - IFNγ, Flow cytometric T-cell cytokine assay
Keywords	rate of progression, optimal epitope, chronic infection

Notes

Correlation between HLA class I and spontaneous control of HIV-1 was significant for 7-8 epitopes when 341 chronic, HIV-infected subjects, divided into controllers and non-controllers, were tested for EliSpot responses to 257 optimally defined epitopes. 21 epitopes were associated with viral progression. Protective epitopes tend to cluster in regions of critical stability for the protein, therefore constraining escape.
RRGWEVLKY had a significantly positive association with HLA C*02; it was recognized by 7/46 C*02-positive subjects and 12/295 C*02-negative subjects.

References

Displaying record number 60202

Download this epitope record as JSON.

HXB2 Location	gp160(787-795) gp41(276-284) DNA(8583..8609)	gp160 Epitope Map
Author Location	Env(787-795)
Epitope	`RRGWEVLKY`	Epitope Alignment
Epitope Name	RY9
Species (MHC/HLA)	human(C*14)
Immunogen	HIV-1 infection
Experimental methods	CD8 T-cell Elispot - IFNγ, Flow cytometric T-cell cytokine assay
Keywords	rate of progression, optimal epitope, chronic infection

Notes

Correlation between HLA class I and spontaneous control of HIV-1 was significant for 7-8 epitopes when 341 chronic, HIV-infected subjects, divided into controllers and non-controllers, were tested for EliSpot responses to 257 optimally defined epitopes. 21 epitopes were associated with viral progression. Protective epitopes tend to cluster in regions of critical stability for the protein, therefore constraining escape.
RRGWEVLKY had a significantly positive association with HLA C*14; it was recognized by 3/17 C*14-positive subjects and 9/278 C*14-negative subjects.

References

Displaying record number 54935

Download this epitope record as JSON.

HXB2 Location	gp160(787-795) gp41(276-284) DNA(8583..8609)	gp160 Epitope Map
Author Location
Epitope	`RRGWEVLKY`	Epitope Alignment
Species (MHC/HLA)	human
Immunogen	HIV-1 infection, vaccine
Patient MHC/HLA	014A-009: A01, A02, B08, B38, C04, C06
Experimental methods	CD8 T-cell Elispot - IFNγ, Flow cytometric T-cell cytokine assay
Keywords	vaccine-induced immune responses, acute/early infection

Vaccine Details

Vaccine type	canarypox
Vaccine strain	B clade LAI, B clade MN
Vaccine component	Gag-Pol, gp120, gp41

Notes

T cell responses during early infection in individuals previously enrolled in HIV vaccine trials were compared with those of nonvaccinated subjects.
None of the breakthrough infections possessed vaccine-induced T-cell responses preinfection and 85-86% of vaccinees and nonvaccinees with primary infection developed T-cell responses postinfection, indicating that vaccinees' ability to mount T-cell response postinfection is not compromized by previous immunization.
Breakthrough subjects recognized 43 T-cell epitopes, 8 of them novel, and 25% were present in the vaccine.
This epitope was not contained in the vaccine, but the linked vaccinated patient in whom the study was conducted recognized it after developing infection.

References

Horton2006a Helen Horton, Colin Havenar-Daughton, Deborah Lee, Erin Moore, Jianhong Cao, John McNevin, Thomas Andrus, Haiying Zhu, Abbe Rubin, Tuofu Zhu, Connie Celum, and M. Juliana McElrath. Induction of Human Immunodeficiency Virus Type 1 (HIV-1)-Specific T-Cell Responses in HIV Vaccine Trial Participants Who Subsequently Acquire HIV-1 Infection. J. Virol., 80(19):9779-9788, Oct 2006. PubMed ID: 16973582. Show all entries for this paper.